GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCR2 Therapeutics Inc (NAS:TCRR) » Definitions » EBITDA per Share

TCR2 Therapeutics (TCR2 Therapeutics) EBITDA per Share : $-3.31 (TTM As of Mar. 2023)


View and export this data going back to 2019. Start your Free Trial

What is TCR2 Therapeutics EBITDA per Share?

TCR2 Therapeutics's EBITDA per Share for the three months ended in Mar. 2023 was $-0.94. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $-3.31.

During the past 3 years, the average EBITDA per Share Growth Rate was -9.10% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -28.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for TCR2 Therapeutics's EBITDA per Share or its related term are showing as below:

TCRR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -40.8   Med: -19.45   Max: -8.2
Current: -9.1

During the past 7 years, the highest 3-Year average EBITDA per Share Growth Rate of TCR2 Therapeutics was -8.20% per year. The lowest was -40.80% per year. And the median was -19.45% per year.

TCRR's 3-Year EBITDA Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 6.2 vs TCRR: -9.10

TCR2 Therapeutics's EBITDA for the three months ended in Mar. 2023 was $-36.85 Mil.

During the past 3 years, the average EBITDA Growth Rate was -33.40% per year. During the past 5 years, the average EBITDA Growth Rate was -54.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 7 years, the highest 3-Year average EBITDA Growth Rate of TCR2 Therapeutics was -33.40% per year. The lowest was -73.40% per year. And the median was -63.15% per year.


TCR2 Therapeutics EBITDA per Share Historical Data

The historical data trend for TCR2 Therapeutics's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TCR2 Therapeutics EBITDA per Share Chart

TCR2 Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA per Share
Get a 7-Day Free Trial -1.12 -2.39 -2.40 -2.46 -3.11

TCR2 Therapeutics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -0.81 -0.78 -0.78 -0.94

TCR2 Therapeutics EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

TCR2 Therapeutics's EBITDA per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA per Share(A: Dec. 2022 )
=EBITDA/Shares Outstanding (Diluted Average)
=-120.036/38.628
=-3.11

TCR2 Therapeutics's EBITDA per Share for the quarter that ended in Mar. 2023 is calculated as

EBITDA per Share(Q: Mar. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-36.851/39.221
=-0.94

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TCR2 Therapeutics  (NAS:TCRR) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


TCR2 Therapeutics EBITDA per Share Related Terms

Thank you for viewing the detailed overview of TCR2 Therapeutics's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TCR2 Therapeutics (TCR2 Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 Binney Street, Suite 710, Cambridge, MA, USA, 02142
TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.
Executives
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Ansbert Gadicke director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Mpm Asset Management Llc 10 percent owner 399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Shawn Tomasello director C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Priti Hegde director TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Rosemary Harrison officer: Chief Business & Strategy C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Garry E Menzel director, officer: President & CEO C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Peter Olagunju officer: Chief Technical Officer TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Alfonso Quintas Cardama officer: Chief Medical Officer C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Angela Justice officer: Chief People Officer 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Eric Sullivan officer: Chief Financial Officer GOODWIN PROCTER LLP, 53 STATE ST, BOSTON MA 02109
Mayur Ian Somaiya officer: Chief Financial Officer TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Axel Hoos director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142